BHVN Stock Price, Chart, Stats & News
Biohaven Ltd. (BHVN) does not currently pay a dividend.
BHVN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.20% |
ROA | -163.66% |
ROE | -688.89% |
D/E | 5.36x |
Interest coverage ratio | – |
BHVN valuation
P/E | – |
P/S | – |
P/B | 19.32x |
P/CF | -1.65x |
P/FCF | -1.45x |
P/OCF | -1.65x |
PEG | -0.16x |
EV multiple | -1.13x |
About
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
Similar securities
Based on sector and market capitalization
